Floatz logo

Zelapar

Borderline Personality Disorder

Mood and Anxiety Research, IncPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Borderline Personality Disorder cohort.

Asset / SponsorPhaseRating
LITHIUM, ELEMENTAL
Columbia Northwest Pharmaceuticals
Phase 2B
TEONANACATL
University of Chicago
Phase 2B
CITALOPRAM
Columbia Northwest Pharmaceuticals
Phase 2B
Cipralex
University of Chicago
Phase 2CCC
MIDAZOLAM
Joshua Rosenblat
Phase 2CCC

View all 9 →

Same molecule, other indications

Zelapar is also rated in:

major depressive disorderDormant
BBB
Indicative ·
78 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
68 / 100
View asset →
bipolar depressionDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →